Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029

Niagen Bioscience, Inc.

Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
Initial term through April 30, 2029, with automatic 12-month renewals unless 90-day non-renewal notice.
ChromaDex must purchase minimum annual quantities and provide rolling 24-month forecasts with first 12 months binding.
Parties will negotiate a royalty-bearing license to Grace's NRCL manufacturing patents upon termination under specified conditions.
2025 product price set at $[***]/kg; each party may propose up to 5% price adjustment twice per year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.